Vermillion (NASDAQ:VRML) Stock Price Passes Above 200 Day Moving Average of $0.68

Shares of Vermillion, Inc. (NASDAQ:VRML) crossed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $0.68 and traded as high as $0.83. Vermillion shares last traded at $0.80, with a volume of 165,471 shares.

The firm has a fifty day simple moving average of $0.81 and a 200-day simple moving average of $0.68. The company has a market cap of $78.25 million, a PE ratio of -4.24 and a beta of 3.45. The company has a quick ratio of 4.53, a current ratio of 4.54 and a debt-to-equity ratio of 0.10.

Vermillion (NASDAQ:VRML) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.04) earnings per share (EPS) for the quarter. The firm had revenue of $1.29 million for the quarter. Vermillion had a negative return on equity of 163.08% and a negative net margin of 353.32%.

Hedge funds have recently modified their holdings of the business. Millennium Management LLC purchased a new position in shares of Vermillion during the third quarter worth about $78,000. Russell Investments Group Ltd. purchased a new position in shares of Vermillion during the second quarter worth about $278,000. Perkins Capital Management Inc. purchased a new position in shares of Vermillion during the third quarter worth about $176,000. Finally, Vanguard Group Inc. grew its holdings in shares of Vermillion by 145.8% during the second quarter. Vanguard Group Inc. now owns 1,984,250 shares of the company’s stock worth $1,766,000 after purchasing an additional 1,177,152 shares during the last quarter. 20.23% of the stock is currently owned by institutional investors.

About Vermillion (NASDAQ:VRML)

Vermillion, Inc, together with its subsidiaries, discovers, develops, and commercializes diagnostic and bio-analytical solutions that help physicians to diagnose, treat, and enhance gynecologic health outcomes for women primarily in the United States. The company's diagnostic tests include OVA1, a blood test for the pre-surgical identification of women who are at high risk of having a malignant ovarian tumor; and Overa, a multivariate index assay second generation test to determine the malignancy of ovarian cancer in women.

Further Reading: What does the Producer Price Index (PPI) tell investors?

Receive News & Ratings for Vermillion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vermillion and related companies with's FREE daily email newsletter.